Drug Profile
Palifermin biosimilar - Genemen Biotech
Alternative Names: Lyophilised recombinant human keratinocyte growth factor - Genemen BiotechLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Genemen Biotech
- Class Chemoprotectants; Fibroblast growth factors
- Mechanism of Action Fibroblast growth factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Stomatitis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Stomatitis(In volunteers) in China (IV, Injection)
- 07 Jan 2013 Phase-I clinical trials in Stomatitis (in volunteers) in China (IV)